We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




New Blood Test Can Predict Future Breast Cancer

By LabMedica International staff writers
Posted on 29 Apr 2015
Print article
Image: The Avance III 600 spectrometer for proton nuclear magnetic resonance analysis (Photo courtesy of Bruker).
Image: The Avance III 600 spectrometer for proton nuclear magnetic resonance analysis (Photo courtesy of Bruker).
The analysis of a blood sample could predict if a woman will get breast cancer within two to five years which could create a paradigm shift in early diagnosis of this malignant neoplasm as well as other diseases.

The method, called a metabolic blood profile is still in the early stages but over time the experts expect it could be used to predict breast cancer and more generally to predict chronic disease and the new method will lead to better prevention and early treatment of the disease.

Scientists at the University of Copenhagen (Frederiksberg, Denmark) used 20-year-old blood samples and other available data from 400 women who were healthy when they were first examined but who were diagnosed with breast cancer two to seven years after providing the first sample, and from 400 women who did not develop breast cancer. The team analyzed all compounds contained in the blood sample, instead of as is often done in health and medical science, examining what a single biomarker means in relation to a specific disease.

The plasma samples were analyzed by proton Nuclear Magnetic Resonance (1H NMR). NMR analysis was performed with a Bruker Avance III 600 spectrometer (Bruker Biospin Gmbh; Rheinstetten, Germany). The NMR spectra were subjectively evaluated by spectroscopists and data analysts in order to exclude as many noise regions from the data as possible and to include all peaks in the most parsimonious manner. The spectroscopists and data analysts were blinded to the case/control status.

While a mammography can detect newly developed breast cancer with a sensitivity of 75% the new metabolic blood profile is able to predict the likelihood of a woman developing breast cancer within the next two to five years with a sensitivity of 80%. The method was also used to test a different dataset of women examined in 1997. Predictions based on the new set of data matched the first dataset, which indicated the validity of the model.

Lars Ove Dragsted, PhD, a professor and senior author of the study said, “The potential is that we can detect a disease like breast cancer much earlier than today. This is important as it is easier to treat if you discover it early. In the long term, it will probably also be possible to use similar models to predict other diseases.” The study was published on March 10, 2015, in the journal Metabolomics.

Related Links:

University of Copenhagen 
Bruker Biospin Gmbh


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.